AMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amneal Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was $8.32. Amneal Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 310 Mil. Therefore, Amneal Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was $2,577 Mil.
Amneal Pharmaceuticals's quarterly market cap increased from Mar. 2024 ($1,870 Mil) to Jun. 2024 ($1,965 Mil) and increased from Jun. 2024 ($1,965 Mil) to Sep. 2024 ($2,577 Mil).
Amneal Pharmaceuticals's annual market cap declined from Dec. 2021 ($716 Mil) to Dec. 2022 ($301 Mil) but then increased from Dec. 2022 ($301 Mil) to Dec. 2023 ($1,861 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amneal Pharmaceuticals's Enterprise Value for Today is $5,080 Mil.
The historical data trend for Amneal Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Market Cap | Get a 7-Day Free Trial | 708.88 | 674.87 | 715.69 | 301.47 | 1,860.85 |
Amneal Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Market Cap | Get a 7-Day Free Trial | 651.34 | 1,860.85 | 1,870.26 | 1,965.32 | 2,577.29 |
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amneal Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $6.07 | * | 306.565 | |
= | $1,861 |
Amneal Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as
Market Cap (Q: Sep. 2024 ) | = | Share Price (Q: Sep. 2024 ) | * | Shares Outstanding (EOP) (Q: Sep. 2024 ) |
= | $8.32 | * | 309.77 | |
= | $2,577 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (NAS:AMRX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Deborah M. Autor | director | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
John Kiely | director | C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286 |
Jason B. Daly | officer: SVP, Chief Legal Officer | 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807 |
Andrew S Boyer | officer: Exec VP, Comm Optns | C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960 |
Nikita Shah | officer: SVP, Chief HR Officer | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807 |
Tpg Gp A, Llc | 10 percent owner | 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
Gustavo Pesquin | officer: See Remarks | 4 PARK LANE, MADISON NJ 07940 |
Jon Winkelried | 10 percent owner | C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004 |
Gautam Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807 |
Chirag K. Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Chintu Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807 |
Joseph Todisco | officer: SVP, Specialty Commercial | 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Jeffrey P. George | director | C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Shlomo Yanai | director | ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
Paul M Meister | director | 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862 |
From GuruFocus
By GuruFocus News • 10-09-2024
By Business Wire • 08-20-2024
By GuruFocus Research • 08-17-2024
By Business Wire • 12-04-2024
By Business Wire • 07-01-2024
By Business Wire • 09-05-2024
By Business Wire • 11-21-2024
By Business Wire • 07-29-2024
By Business Wire • 10-08-2024
By GuruFocus News • 11-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.